Investment Rating - The report maintains a BUY rating for Innovent Biologics with a target price of HK$113.86, reflecting a potential upside of 33.2% from the current price of HK$85.50 [3]. Core Insights - Innovent Biologics reported its first-ever full-year net profit of RMB834 million for FY25, with revenue reaching RMB13.0 billion, representing a 38% year-over-year growth. Product sales increased by 45% year-over-year to RMB11.9 billion [1]. - The company is advancing its transition to a fully integrated global biopharma through strategic partnerships, including a collaboration with Takeda for IBI363 and a US$350 million upfront payment from Eli Lilly for early-stage assets [5]. - Innovent's product gross margin improved to 86.2% in 2H25, and the selling expense ratio decreased to 48.0% for FY25, despite a slight increase in 2H25 [1]. - The company has a strong pipeline with plans to advance at least five assets into global Phase 3 multi-regional clinical trials (MRCTs) by 2030, including IBI363 and IBI324, which is expected to disrupt the global retinal market [5]. - R&D expenses are projected to rise as global MRCTs advance, with a cash reserve of RMB24.3 billion as of the end of 2025, positioning Innovent well for its global ambitions [1]. Financial Summary - FY25 revenue was RMB13.0 billion, with a year-over-year growth of 38% and net profit of RMB834 million [1]. - Revenue projections for FY26, FY27, and FY28 are RMB16.6 billion, RMB20.9 billion, and RMB26.1 billion, respectively, with corresponding year-over-year growth rates of 27.6%, 25.7%, and 24.7% [2]. - The report indicates that net profit is expected to reach RMB2.1 billion in FY26, RMB3.4 billion in FY27, and RMB4.6 billion in FY28 [2]. Share Performance - The market capitalization of Innovent Biologics is approximately HK$148.36 billion, with an average turnover of HK$944 million over the past three months [3]. - The stock has shown a 1-month absolute performance of 0.5% and a 3-month performance of 5.9% [5].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 105.00, indicating a potential upside of 17.1% from the current price of HKD 89.65 [1][9]. Core Insights - The company has successfully secured a strategic partnership with Eli Lilly, marking its seventh collaboration and validating its antibody technology platform. This partnership is expected to significantly enhance the company's overseas development of early-stage assets and increase global commercialization certainty [2][7]. - The company anticipates strong commercial growth driven by its comprehensive pipeline in 2026, with projected product revenue growth of approximately 45% year-on-year to RMB 12.505 billion in 2025. Key products are expected to continue providing stable support for revenue growth [7][12]. - The management expects that three key assets, IBI363, IBI343, and IBI324, will enter global Phase III clinical trials, with IBI363 alone projected to contribute over USD 40 billion to the market [7][12]. Financial Forecast Changes - Revenue projections for 2025 have been revised down to RMB 12.505 billion, a decrease of 37.1% from previous estimates, while 2026 revenue is expected to rise to RMB 18.450 billion, an increase of 26.7% [3]. - Gross profit for 2025 is now forecasted at RMB 10.713 billion, down 41.0%, with a gross margin of 85.7%. For 2026, gross profit is expected to increase to RMB 16.064 billion, with a gross margin of 87.1% [3]. - The net profit forecast for 2025 has been significantly reduced to RMB 1.055 billion, a decrease of 87.9%, while 2026 net profit is projected to rise to RMB 3.502 billion, reflecting a 37.8% increase [3]. Stock Performance - The stock has shown a year-to-date increase of 17.57%, with a 52-week high of HKD 107.00 and a low of HKD 35.50, indicating strong market interest [6][11]. Valuation Model - The DCF valuation model estimates the equity value at RMB 161.238 million, translating to a per-share value of HKD 105.00, based on projected free cash flows and a WACC of 9.9% [8][15].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 105.00, indicating a potential upside of 17.1% from the current price of HKD 89.65 [1][9]. Core Insights - The company has successfully secured a strategic collaboration with Eli Lilly, marking its seventh major partnership and validating its antibody technology platform. This collaboration is expected to significantly enhance the company's overseas development of early-stage assets and increase global commercialization certainty [2][7]. - The company anticipates strong commercial growth driven by its oncology and comprehensive pipeline in 2026, with projected product revenue growth of approximately 45% year-on-year to RMB 12.505 billion in 2025. Key products are expected to continue supporting revenue growth [2][7]. - The report highlights the potential market space for key assets, estimating over USD 60 billion, with IBI363 alone contributing more than USD 40 billion. The company is also expected to introduce 8-10 new molecules annually from its innovation pipeline starting in 2026 [2][7]. Financial Forecast Changes - Revenue projections for 2025 have been revised down to RMB 12,505 million, a decrease of 37.1% from previous estimates. However, the 2026 revenue forecast has been increased by 26.7% to RMB 18,450 million, and the 2027 forecast has been raised by 18.6% to RMB 20,830 million [3]. - Gross profit for 2025 is now expected to be RMB 10,713 million, down 41.0% from prior estimates, while the gross profit margin is projected to be 85.7% [3]. - The net profit forecast for 2025 has been significantly reduced to RMB 1,055 million, reflecting an 87.9% decrease from previous estimates, but is expected to rise to RMB 3,502 million in 2026 and RMB 4,341 million in 2027 [3]. Stock Performance - The stock has shown a year-to-date increase of 17.57%, with a 52-week high of HKD 107.00 and a low of HKD 35.50, indicating strong market interest [6][12]. Valuation Model - The discounted cash flow (DCF) valuation model estimates the equity value at RMB 161,238 million, translating to a per-share value of HKD 105.00, based on projected free cash flows and a WACC of 9.9% [8][15].

Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly marks their seventh partnership, focusing on the development of innovative drugs in oncology and immunology, with significant financial implications for Innovent [2][5]. Financial Aspects - Innovent will receive an upfront payment of $350 million and may earn up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [2]. - The company’s stock price rose by 7.42% to HKD 85.4 per share, with a market capitalization nearing HKD 150 billion as of February 9 [3]. Historical Context - The partnership dates back to 2015, yielding successful products such as the PD-1 antibody, Sintilimab, and the GLP-1 receptor agonist, MaShidu [4]. - Sintilimab has been a cornerstone of Innovent's commercialization strategy, rapidly entering the domestic market and becoming a key product in their portfolio [4]. Strategic Development - The collaboration emphasizes a new model of business development, focusing on entirely new targets and molecules rather than existing products [2][5]. - Innovent will lead the projects from drug discovery to clinical validation in China, while Eli Lilly retains global rights outside of Greater China [5]. Industry Trends - The partnership reflects a broader trend where multinational pharmaceutical companies are increasingly interested in early-stage innovative assets from Chinese firms, moving away from established clinical pipelines [6]. - This shift is seen as a necessary evolution in the research paradigm, allowing for systematic validation of technologies across multiple targets while managing costs [6]. Future Outlook - Innovent's product revenue is projected to reach approximately CNY 11.9 billion in 2025, marking a 45% year-on-year increase, with significant contributions from its oncology and chronic disease product lines [8]. - The company has three core assets expected to enter or are already in international Phase III clinical trials, with a combined market potential exceeding $60 billion [8][9]. Product Pipeline - The new generation IO therapy, IBI363, is anticipated to have a market potential exceeding $40 billion, while IBI343 and IBI324 are also expected to contribute significantly to revenue, with market potentials of over $8 billion and $15 billion, respectively [9][10].